Intellia Therapeutics, Inc.
At Close: 4:00 PM
NTLA Stock Price Graph
NTLA Stock Price Today
Intellia Therapeutics, Inc. (NTLA) stock declined over -0.90% intraday to trade at $30.75 a share on NASDAQ. The stock opened with a loss of -16.97% at $25.45 and touched an intraday high of $25.45, rising 0.33% against the last close of $30.65. The Intellia Therapeutics, Inc. in stock market went to a low of $23.01 during the session.
NTLA Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
NTLA Stock Price History Chart
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Frequently Asked Questions
What is the current Intellia Therapeutics, Inc. (NTLA) stock price?
Intellia Therapeutics, Inc. (NASDAQ: NTLA) stock price is $30.75 in the last trading session. During the trading session, NTLA stock reached the peak price of $25.45 while $23.01 was the lowest point it dropped to. The percentage change in NTLA stock occurred in the recent session was -0.90% while the dollar amount for the price change in NTLA stock was -$0.28.
NTLA's industry and sector of operation?
The NASDAQ listed NTLA is part of Biotechnology industry that operates in the broader Healthcare sector. Intellia Therapeutics, Inc. , a genome editing company, focuses on the development of therapeutics.
Who are the executives of NTLA?
Dr. David Lebwohl M.D.
Executive Vice President & Chief Medical Officer
Mr. Glenn G. Goddard CPA
Executive Vice President, Chief Financial Officer & Treasurer
Dr. John M. Leonard M.D.
Pres, Chief Executive Officer & Director
Dr. Laura Sepp-Lorenzino Ph.D.
Executive Vice President & Chief Scientific Officer
How NTLA did perform over past 52-week?
NTLA's closing price is 0.35% higher than its 52-week low of $23.01 where as its distance from 52-week high of $57.49 is -0.43%.
How many employees does NTLA have?
Number of NTLA employees currently stands at N/A. NTLA operates from 40 Erie Street, Cambridge, MA 02139, US.
Link for NTLA official website?
Official Website of NTLA is: https://www.intelliatx.com
How do I contact NTLA?
How many shares of NTLA are traded daily?
NTLA stock volume for the day was 1079517.00 shares. The average number of NTLA shares traded daily for last 3 months was 1.21 Million.
What is the market cap of NTLA currently?
The market value of NTLA currently stands at $2.75 Billion with its latest stock price at $30.75 and N/A of its shares outstanding.